RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:WOWActually they are land locked as the two businesses have to be completely separate, as explained by Boris himself:
The European business is totally legal within Europe, whereas the US business is legal on a State-by-State basis, but has this quirkiness where it’s still not legal on a federal basis. That could put the European business under threat with regulators. And so, what we did was we structured this deal from our holding company in Canada, where it’s absolutely legal, Federally legal in Canada. So, we bought the company from there, and we capitalized the European subsidiary with money out of Europe. So, there is no money flow between the US companies and the European companies. So, it’s going to be run as an independent company with its own board, its own management team in Europe, run by Europeans. And I will be there, like I am at Curaleaf as the founder, I’ll be there on the board as chairman mentoring the team in the way we build it out. And of course, there will be some cross fertilization and R&D. There’ll be some branding that will be lumped together and some marketing that’ll be done together. But we’re not going to have any kind of financial integration from that perspective, and we’re really going to run the business. I mean, Antonio is going to continue. He was the founder of EMMAC, and he’s going to continue to be. He’s very highly incentivized, and he’s going to stay as the CEO of that business, and he’s going to run that business in Europe separately. So, that’s the way we’ve decided to build it. And frankly, I think it’s the right way. I think many American companies sometimes have made mistakes when they’ve gone abroad and trying to bring their business practices everywhere, and it doesn’t work. And since I actually started my career in Europe and spent the bulk of my career in Europe, I see it a little bit differently. And so, I really want to build a European Curaleaf business, which may be a bit different than the US business.